11611 N. MERIDIAN ST, CARMEL, IN
Material disclosure
Other Events
Annual Meeting Held; 10,206,763 Votes Cast by Shareholders
Annual Report to Security Holders
At The Market Offering Agreement with Craig-Hallum Capital Group
Neuraxis, Inc. Reports Preliminary Q1 2026 Financial Results
FDA 510(k) Clearance for NeurAxis' PENFS Technology for FAP Treatment
Neuraxis, Inc. Reports Q3 2025 Financial Results and Cash Position
Q2
Q1
FY 2025
Q3
FY 2024
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload